Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Omeprazole DDI Study with Anagrelide (SPD422) in Healthy Adults
NCT03866434Phase 1Completed
- Sponsor
- Takeda
- Start
- Feb 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of anagrelide in essential thrombocythemia (ET), sponsored by Takeda. Primary endpoints: Maximum Observed Plasma Concentration of Anagrelide at Day 8, Maximum Observed Plasma Concentration of 3-Hydroxy-Anagrelide at Day 8 and 4 more. Started Feb 2019; status: completed.
02
Drugs
anagrelide
03
Conditions
essential thrombocythemia (ET)
Beyond the preview
Go deeper on NCT03866434.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03866434.